Markers brain natriuretic peptide

This expectation is supported by other observations using the surrogate marker brain natriuretic peptide (BNP), a most sensitive indicator of myocardial hypertrophy and cardiac impairment [23], The expected curbing of cardiotoxicity in WBZ 4 anticancer therapy was confirmed by examining the mRNA levels of BNP in the left ventricle of mice from the same groups assayed for anticancer activity. The BNP mRNA levels were about 58% higher in the ventricles from imatinib-treated animals (Fig. 8.11b), while no significant difference was detected... 

Once vasodilatation was considered to be a good strategy, as it improves HF symptoms. However later studies showed that the disease itself was not influenced. The accent of HF treatment has moved to progression prevention with rigorous suppression of the renin angiotensin aldosterone system. Therapy with /3-blockers was also proven to be effective for the reduction of mortality. These treatments should be started early and the evaluation of their effectiveness in individual patients is difficult. As brain natriuretic peptide (BNP) is produced by the heart and more BNP is released in heart failure, the measurement of BNP in the blood has become popular as surrogate marker for the severity of heart failure and for the response of treatment for heart failure. 

Jougasaki, M., Nishimura, R. A., Bailey, K. R., Saito, Y, Nakao, K., Redeield, M. M. (1996). Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28, 988-994. 

Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000 18 1121-8. 

Elevated plasma brain natriuretic peptide (BNP) levels and reduced 6MWD may be surrogate markers of PAH in patients with IPF (163). In one study, 39 patients with pulmonary fibrosis and severe restriction (FVC <55% predicted) had RHC, plasma BNP levels, and 6MWT (163). Among 28 patients with IPF, elevated levels of BNP correlated with increased PAP and pulmonary vascular resistance (PVR) and correlated inversely with 6MWD. Interestingly, PFTs did not correlate with either BNP or PAH (163). 

Newer markers that identify patients at high risk of mortality or reinfarction that are under development but have not been incorporated currently into routine patient care include C-reactive protein, a maker of vascular inflammation elevated serum creatinine or reduced creatinine clearance, identifying patients with chronic kidney disease and brain (B-type) natriuretic peptide (BNP), which is released predominately from ventricular myocytes in response to cell stretch as the infarct remodels. Dialysis patients have a 1-year mortality rate of more than 40% following a first MI. ... 

---